Home
overview

SMi proudly present their 10th annual Asthma and COPD conference taking place in Central London on Wednesday 2nd and Thursday 3rd April, 2014. 

This year’s event will focus on the cutting edge concepts driving the developments of asthma and COPD forward.


There is a growing demand for the next generation of inhaled combination products and novel therapeutics. This conference will enable delegates to gain valuable insight into the latest ground-breaking advances in the respiratory drug market. It will focus on the challenges and strategies to enhance patient outcomes, providing extensive knowledge from the key leading industry and academic experts.

The agenda will focuss on the treatment for exacerbations, clinical trial design and strategies for method enhancement, biomarkers and the utilisation of devices for Asthma and COPD. Key focus will be put on the anti-inflammatory developments in addition to the efficacy and toxicological issues relating to combination products.

Insight will be given on the current regulatory requirements and enable delegates to stay up to date with the guidelines.

A new session for 2014 will look at Cystic fibrosis, how does this relate to the developments within asthma and COPD?

 


 

• Hear from leading industry and academic experts on the latest cutting-edge pre-clinical and clinical developments driving Asthma and COPD forward
• Discuss and evaluate the developments in the treatment for exacerbations
• Evaluate clinical trial design and strategies utilised for method enhancement
• Gain more in-depth knowledge on biological developments in addition to efficacy and toxicological issues relating to combination products.
• Key insight will be given regarding the current regulatory requirements enabling delegates to stay up to date with the guidelines
 

Chief Executives, Chief Scientific Officers, Chief Medical Officers, Vice Presidents, Heads, Directors, Senior Scientist, Principle Scientists, Clinicians, Physicians, Project Leaders, Specialists, and Managers in the following areas:


• Respiratory Physiology & Medicine
• Respiratory Pharmacology
• Regulatory and Medical Affairs
• Inflammatory Disease
• Respiratory, Inflammation and Autoimmunity
• Pulmonary Disease
• Respiratory Therapeutics
• Immunology
• Medical & Inhalation Devices
• In-Vitro Biology
• Biomarker • Inflammation Discovery
• Preclinical R&D
• Clinical Pharmacology
• Clinical Trials
• Research and Development
• Business Development
• Brand Manager
• Commercial
• Respiratory
 

3M Health Care; Aerocrine Inc; AlgiPharma AS; Almirall; APTAR PHARMA; Asthma Uk; Axikin; Biomedical Systems; Biopharm Insight; F. Hoffmann-La Roche Ltd.; Family medicine specialist; Fidelta; Glenmark Pharmaceuticals Europe Ltd; GSK Vaccines; Hammersmith Medicines Research; Hoffmann-La Roche; Imperial College; Imperial College School of Medicine (N.H.L.I.); International Medical Press; Kyorin Pharmaceutical Co Ltd; Manchester University; MedImmune; Morphosys A G; Novartis; Novartis Horsham Research Centre; Oxagen Ltd; Prosonix Ltd; Pulmagen Therapeutics; Sanderling Ventures; Synairgen Ltd; Teva UK Ltd; The Pediatric Care Center; Thomson Reuters; UCB-Celltech; University Of Marburg; University of Nottingham; Vectura; Via Lactea 342 Jardines de Satelite; Vitalograph;

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Jørgen Vestbo

Jørgen Vestbo, Professor of Respiratory Medicine, Hvidovre Hospital University of Copenhagen

9:10 Eclipse Observational Study for COPD

Jørgen Vestbo

Jørgen Vestbo, Professor of Respiratory Medicine, Hvidovre Hospital University of Copenhagen

• Assess how to measure inflammatory biomarkers to enhance patient outcomes
• Review the monitoring of patients over a 3 year period, and how this links to biomarkers with clinical outcomes
• What can we infer for treatment – what can we learn from biomarkers to enhance clinical trial outcomes

9:50 Assessing potential new respiratory developments for market penetration

• TD-4208, an inhaled once-daily dosed Long-Acting Muscarinic Antagonist (LAMA) for the treatment of COPD                                                                                                                                                                                
• TD-5959/GSK-081, a multivalent Muscarinic Antagonist Beta2 Agonist (MABA) for the treatment of COPD

Brett Haumann

Brett Haumann, Vice President, Clinical Development and Operations , Theravance, Inc

Paul  Meunier

Paul Meunier, Executive Director, Inhaled Product Development , Theravance, Inc

10:30 Morning Coffee

11:00 Biomarker developments for respiratory drug assessment

Paul Whittaker

Paul Whittaker, Unit Head for Pre-Clinical Biomarkers, Novartis Horsham Research Centre

• The heterogeneity of respiratory diseases poses a challenge for drug development
• Successful therapy will require the differential treatment of disease subgroups by defining the clinical subphenotype and matching the relevant drug(s) to that subphenotype
• The identification of biomarkers to enable patient stratification and provide support for efficacy of novel compounds in early clinical trials will be a key part of this process
 

11:40 Evaluating patient stratification to enhance clinical trial design

Matthew Catley

Matthew Catley, Team Leader RIA, AstraZeneca

• Asthma as a heterogenic disease
• Why patient stratification is essential to clinical success
• Lessons from anti-IL-5 and anti-IL-13
• Where do we stand with COPD?

 

12:20 Networking Lunch and Round Table Discussions

13:30 Clinical Trial Effectiveness - Assessment of Asthma and COPD

Ewan Walters

Ewan Walters, Medical Director, Teva UK Ltd

• Reviewing PK data for combination therapies
• Assessing real life studies for practicalities
• Computerised management for GPs in Asthma and COPD
• Evaluating the burden of disease model

14:10 Inhalation devices - evolution or revolution to address patient, health care professional and payor needs?

Roy Chapple

Roy Chapple, Business Development Manager , 3M Healthcare Limited

  • Past, present and near future of inhalation devices
  • What's the problem? Recent 3M research to understand current issues and future needs of patients, health care professionals and payors.
  • Evolution or revolution?
  • 14:50 Afternoon tea

    15:20 Enhancing drug delivery through devices for Asthma and COPD

    Omar  Usmani

    Omar Usmani , Clinical Senior Lecturer and Consultant Physician , Imperial College Of Science And Medicine


     
    • Reviewing clinical device equivalence for safety and performance enhancement 
    • What are the revolutionary advancements in respiratory assessment 
    • MDI’s and DPI’s delivery of devices – what are the next generation of devices for inhaled respiratory medicines

    16:00 Making the National Institute for Health Research infrastructure work for Pharma

    Anthony  De Soyza

    Anthony De Soyza, Clinical Senior Lecturer/Consultant, Newcastle University

  • Understanding what makes the UK an attractive destination for delivering trials
  • How the NIHR Respiratory speciality group has worked to aid Pharma
  • How evidence fror incorporation into
  • 16:40 DISCUSSION PANEL

    Ewan Walters

    Ewan Walters, Medical Director, Teva UK Ltd

    Anthony  De Soyza

    Anthony De Soyza, Clinical Senior Lecturer/Consultant, Newcastle University

    Roy Chapple

    Roy Chapple, Business Development Manager , 3M Healthcare Limited

    Nicolas  Touchot

    Nicolas Touchot , Consultant , Therachallenges

    17:20 Chairman's Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Noel  Snell

    Noel Snell, Director of Research , British Lung Foundation

    9:10 U-BIOPRED Observational Study for Asthma


    • Reviewing the history and set-up of U-BIOPRED
    • Assessing the protocol and plans for the future
    • Insight into the clinical academic initial data from the study
    • Industry perspective- How could this collaboration make for a beneficial output?

    Noel  Snell

    Noel Snell, Director of Research , British Lung Foundation

    Fan Chung

    Fan Chung, Professor of Respiratory , National Heart and Lung Institute Imperial College London

    Chris Compton

    Chris Compton, VP, Novartis Horsham Research Centre

    Peter Howarth

    Peter Howarth, Professor of Allergy and Respiratory Medicine, University Of Southampton School Of Medicine

    10:40 Morning Coffee

    11:10 Regulatory perspectives in the clinical development of fixed dose combination inhaled drugs

    Nithyanandan Nagercoil

    Nithyanandan Nagercoil , Senior Medical Assessor , MHRA

  • Guidelines & its impact on the clinical development plan
  • Scientific Advice during development
  • Issues during Assessment
  • 11:50 Discussion Panel


     • Assessing the current development stage of Asthma and COPD guidelines and reviewing the specific guidance that is out for consultation
    • Evaluating fixed-dose combinations and long-term cardiovascular safety for inhaled drugs
    • What are exacerbations and are they a good choice of primary end-point?

    Nithyanandan Nagercoil

    Nithyanandan Nagercoil , Senior Medical Assessor , MHRA

    John Warren

    John Warren, Director, Medicines Assessment

    Christine  Ward

    Christine Ward , Translational Medicine Lead, MedImmune

    12:30 Networking Lunch and Road Table Discussions

    13:30 Moving forward in Respiratory - Market Access

    Nicolas  Touchot

    Nicolas Touchot , Consultant , Therachallenges

    • Identifying  Payer Value Elements in COPD and Asthma
    • Addressing potential Payer Value uncertainties
    • Using Market Access to competitive advantage

    14:10 KEYNOTE ADDRESS

    Christine  Ward

    Christine Ward , Translational Medicine Lead, MedImmune


    • Ensuring better disease control by stopping inflammation caused by the virus 
    • Understanding the comparison and contrast of postganglionic fibre receptors
    • Reviewing the use of mAbs to treat severe asthma and inflammation 
    • Assessing what the translational model issues are for exacerbations using computational models for potential disease progression 

    14:50 Afternoon Tea

    15:20 Development of Antivirals for the treatment/prevention of Virus Induced Exacerbations of Asthma and COPD

    Phillip Monk

    Phillip Monk, Chief Scientific Officer , Synairgen Ltd

    • Unmet clinical need
    • Target mechanisms: pathogen or host?
    • Therapies in Development
    • Future therapeutic options

    16:00 RPL554 as a novel dual PDE3 and 4 inhibitor for the treatment of Asthma and COPD

    Jan-Anders Karlsson

    Jan-Anders Karlsson, CEO , verona pharma.

    • COPD is one of the most common chronic diseases in the world, and the prevalence is increasing
    • COPD is one of the most common causes of hospitalization in UK
    • More effective treatments are needed to reduce exacerbations and hospitalizations
    • RPL554 is an effective bronchodilator with anti-inflammatory properties
    • RPL554 is a novel, inhaled treatment for patients with severe COPD, currently in Phase 2 clinical trials

    16:40 Chairman’s Closing Remarks and Close of Day Two

    +

    FEATURED SPEAKERS

    Christine  Ward

    Christine Ward

    Translational Medicine Lead, MedImmune
    Nithyanandan Nagercoil

    Nithyanandan Nagercoil

    Senior Medical Assessor , MHRA
    Noel  Snell

    Noel Snell

    Director of Research , British Lung Foundation

    Anthony De Soyza

    Clinical Senior Lecturer/Consultant, Newcastle University
    Anthony  De Soyza

    Brett Haumann

    Vice President, Clinical Development and Operations , Theravance, Inc
    Brett Haumann

    Chris Compton

    VP, Novartis Horsham Research Centre
    Chris Compton

    Christine Ward

    Translational Medicine Lead, MedImmune
    Christine  Ward

    Ewan Walters

    Medical Director, Teva UK Ltd
    Ewan Walters

    Fan Chung

    Professor of Respiratory , National Heart and Lung Institute Imperial College London
    Fan Chung

    Jan-Anders Karlsson

    CEO , verona pharma.
    Jan-Anders Karlsson

    John Warren

    Director, Medicines Assessment
    John Warren

    Jørgen Vestbo

    Professor of Respiratory Medicine, Hvidovre Hospital University of Copenhagen
    Jørgen Vestbo

    Matthew Catley

    Team Leader RIA, AstraZeneca
    Matthew Catley

    Nicolas Touchot

    Consultant , Therachallenges
    Nicolas  Touchot

    Nithyanandan Nagercoil

    Senior Medical Assessor , MHRA
    Nithyanandan Nagercoil

    Noel Snell

    Director of Research , British Lung Foundation
    Noel  Snell

    Omar Usmani

    Clinical Senior Lecturer and Consultant Physician , Imperial College Of Science And Medicine
    Omar  Usmani

    Paul Meunier

    Executive Director, Inhaled Product Development , Theravance, Inc
    Paul  Meunier

    Paul Whittaker

    Unit Head for Pre-Clinical Biomarkers, Novartis Horsham Research Centre
    Paul Whittaker

    Peter Howarth

    Professor of Allergy and Respiratory Medicine, University Of Southampton School Of Medicine
    Peter Howarth

    Phillip Monk

    Chief Scientific Officer , Synairgen Ltd
    Phillip Monk

    Roy Chapple

    Business Development Manager , 3M Healthcare Limited
    Roy Chapple

    INTERVIEW WITH CHRISTINE WARD, PRINCIPLE SCIENTIST, TRANSLATIONAL MEDICINE-RIA, MEDIMMUNE

    Download

    Marriott Regents Park

    128 King Henry's Road
    London NW3 3ST
    United Kingdom

    Marriott Regents Park

    This 4 star north London hotel in zone 2 is the perfect destination for the astute business traveler as well as the leisure guest that knows how convenient north London hotels are, as a base from which to explore the city .Bond Street is just 3 stops from Swiss Cottage underground station on the Jubilee Line, so you can be shopping, exploring the sights and taking in one of London’s world-renowned West End shows in less than 15 minutes when you stay at this hotel near central London. At the same time, the hive of activity that is Camden Town, the chic shops, cafes and restaurants of Primrose Hill and ZSL’s London Zoo in Regents Park are all just a short walk from this hotel in north London.

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.